Aurobindo Pharma has received support from Biotechnology Industry Research Assistance Council (BIRAC), set up by Department of Biotechnology (DBT) for COVID-19 vaccine developing by the company under the National Biopharma Mission. Government of India has facilitated the establishment of the r-VSV vaccine manufacturing platform for the first time in India.
Aurobindo is in the process of setting up a state-of-art manufacturing facility for viral vaccines which will be used to produce the COVID-19 vaccine and other viral vaccines. The plant will comply to global standards. The Company’s COVID-19 vaccine development is going as per plan.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
